about
Predicting clinical trial results based on announcements of interim analysesBiomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewEarly goal-directed resuscitation of patients with septic shock: current evidence and future directionsChildren's Oncology Group's 2013 blueprint for research: renal tumorsBiomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsRecent developments in clinical trial designs for HIV vaccine researchOvercoming research barriers in Chagas disease-designing effective implementation science.Developing safety criteria for introducing new agents into neoadjuvant trialsIt's about time: lessons for solid tumors from chronic myelogenous leukemia therapyRethinking Phase II Clinical Trial Design in Heart Failure.Systemic therapies for inflammatory eye disease: past, present and futureThe combinatorial complexity of cancer precision medicine.Precision medicine clinical trials: defining new treatment strategies.Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.Adaptive clinical trial designs in oncology.Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire ResponsesThe Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial.Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study.Methods in comparative effectiveness research.An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumorsBayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Pharmacogenomics in clinical practice and drug development.Models of excellence: improving oncology drug development.Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.From drug discovery to biomarker-driven clinical trials in lymphomaNCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Adaptive Randomization of Neratinib in Early Breast Cancer.Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.Adaptive designs for dual-agent phase I dose-escalation studies.Rapid learning for precision oncology.Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.Practical characteristics of adaptive design in phase 2 and 3 clinical trials.Emerging innovations in clinical trial design.Utilizing next-generation sequencing in the management of multiple myeloma.
P2860
Q24288918-A48D4143-B76E-4784-99BA-89121AFDD723Q26766584-5CDB345F-E3B7-44C0-82B1-23FD8B57E97BQ26796483-913F9321-FDA4-4CEA-8EF5-E8405D336C8CQ27000449-F4D7F79A-E119-4AD3-B151-B14D51E3A157Q27010096-9A7973F6-94E3-4844-AAAE-25E32707EBF1Q28066709-E096D122-7AB2-4559-974F-B711A08B2D6DQ28083514-648889F0-EDEF-4FA9-A8C2-F2FAB70AF375Q30244172-17B9EF7F-156E-4462-AD7E-1F66F3A72A23Q33895825-4A7825F8-2DBF-43F5-A0A0-153C06203D2FQ33936071-C26A82B5-A5C2-4EA2-B9EA-08F93F9E3540Q34377514-946639F3-947B-412F-91A6-1E0ADFCF099CQ34687332-1144F91F-828D-48BD-8EA8-D18E6DF34ECCQ34781332-4E73DEFF-F2A3-4C7F-A00C-AF6B90D956E9Q34794577-98E6EF44-4816-4C57-9E09-69A9FF6CA09AQ34886822-9EB8EBE8-14D4-4A46-82D1-0926EE11395FQ35005736-93563331-D43A-4C8B-AF99-5375F04EB3BFQ35206844-CFB81B12-3F28-4745-B63A-279A9A5A13C6Q35666129-963CEC03-3543-443E-AA9E-71CE6F6DE628Q35687969-0663E86A-95BA-4333-80EF-28ED80F1570AQ35892395-E9A9C8C5-C3A6-4EAC-B6D1-0959599C6FB2Q36158310-16EE96EC-87EC-4916-B715-FBA1DBA13FCEQ36288987-A9DEDDE6-8BC4-4325-8729-BC3989238058Q36326130-9FC2A826-36E6-4C62-8E3A-126671F0AFEEQ36417734-CB00DA9A-6869-40F0-99F0-4A8A3F2EC010Q36779225-3DA83930-F721-4C24-B98A-4789D4C11D44Q37238720-F2585170-1830-43DE-9EDC-5E41CAFF4AE9Q37284234-5D2418A9-FD66-410D-B14C-48008C00D355Q37334405-7521BDE5-AFF0-47ED-8BD3-CDFE0472C172Q37392513-B3C0913B-FB13-4F37-B05A-37725820F281Q37551148-38A83338-E0E9-4B23-BB2C-C1ABA392BB9BQ37590339-567B2E5E-89DC-4E72-B039-58A66EFB3913Q37601709-D9EE320F-59D3-4E0B-9B3B-EC93CF93ED38Q37601722-1667DEB5-CB85-4DDD-8C1E-8606327DBBEEQ38090897-2A00CB70-25E8-4584-A697-B14AB64A6A0AQ38180318-077A5216-870C-489C-8128-D5B1D8C8310FQ38371675-FBD97993-175F-4EA9-BCBD-F8AFBFB57A05Q38447119-83C6E082-13E8-42B7-BE9E-ED3290E6FB76Q38603746-2211D75D-2557-4DA5-AA90-3B5ED4E35CA7Q38631473-B7F6A948-E429-49B2-BE2D-A561F582793CQ38681814-73D32EDF-873C-44CA-A555-94665D831F98
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Adaptive clinical trials in oncology.
@en
Adaptive clinical trials in oncology.
@nl
type
label
Adaptive clinical trials in oncology.
@en
Adaptive clinical trials in oncology.
@nl
prefLabel
Adaptive clinical trials in oncology.
@en
Adaptive clinical trials in oncology.
@nl
P2860
P1476
Adaptive clinical trials in oncology.
@en
P2093
Donald A Berry
P2860
P304
P356
10.1038/NRCLINONC.2011.165
P407
P577
2011-11-08T00:00:00Z